Vascular Screening Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Desk Research

To set a clean starting point, we first map which vascular risk conditions are covered and where these tests are typically performed, then align that mapping with public data signals. Desk research uses sources such as the World Health Organization for cardiovascular risk context, CDC publications for screening and risk-factor prevalence, and OECD health statistics for procedure and utilization proxies in major countries.

We also reference sources such as the US FDA device databases for product clearances and indications, peer-reviewed clinical journals for screening pathway norms, and trade and customs statistics where device trade patterns are relevant. Company annual reports, investor presentations, and reputable health care press help confirm product positioning and broad pricing direction. In a few cases, we use paid subscriptions for company financials and patent databases to validate timelines and innovation intensity. These examples are not exhaustive, and many other public sources were also used for data collection, validation, and clarification.

Primary Interviews and Surveys

Primary interviews focus on validating what portion of vascular risk assessment is actually conducted with dedicated screening systems, and how purchasing and utilization differ across hospitals and diagnostic centers. We speak with a mix of device-focused executives, clinical leaders, and operational managers, then cross-check assumptions on typical test volumes, replacement cycles, and average selling price ranges by region. For global coverage, inputs are balanced across mature and emerging health systems so regional shares do not get over-weighted by one geography.

Distribution of primary research fieldwork respondents

Market sizing starts from a top-down build, where country-level demand pools are reconstructed using vascular disease risk prevalence, screening adoption in target age bands, typical tests per patient per year, and the split of tests done in hospitals versus diagnostic centers. Those volumes are translated into revenue using practical price bands for portable and standalone systems, and then adjusted for replacement cycles and utilization intensity.

After forming the first totals, we corroborate the direction using selective bottom-up approximations, including supplier revenue checks, channel feedback on shipment momentum, and sampled ASP checks implied by unit volumes in key countries. When gaps appear, they are typically linked to uneven penetration assumptions, bundled pricing, or undercounted demand from smaller facilities. In those cases, we rebalance the model using interview-backed ranges.

Forecasting is built with scenario analysis tied to trend lines in aging population, diabetes burden, preventive care emphasis, and technology shift toward portable systems. Growth rates are stress-tested using expert views on reimbursement sensitivity and capital budget cycles, then applied consistently across regions so the final forecast remains traceable and repeatable.

Outputs are checked against independent signals, including regional health spending direction, device approval cadence, and expected replacement demand, before final review. If a country shows an unusual jump or drop, we trace the driver back to volume, price, or mix assumptions, then review the outlier again with at least one additional external input.

A multi-step analyst review is followed so calculations, units, and currency handling remain consistent across the time series. The report is refreshed annually, and interim updates are made when material events occur, such as major policy shifts or large product launches. Before delivery, the model is re-opened for a fresh pass so the most current market signals are reflected.

Published market values for vascular screening do not always align because firms often count different revenue streams, use different base years, and assume different rates of portable systems replacing standalone systems. Currency conversion timing, and whether services and software are included, can also change the headline number even when the narrative appears similar.

In our checks, the largest spread typically comes from whether the estimate is device-only or includes screening services, software, and consumables, and whether the base year is anchored to a utilization-led demand pool or a forecast-led revenue curve. The device-only, product-type, and end-user-aligned scope, with 2026 treated as the sizing year and then validated through utilization and pricing checks, explains where the 2026 figure in the table lands, reflecting the approach applied by Mordor Intelligence.

Benchmark comparison

Across the three figures, the range is mainly explained by what gets counted as market revenue and how the starting year is set. When scope is kept tight to screening systems and inputs are tied back to test volumes, setting mix, and price bands, the market size stays traceable to clear drivers and is easier to update consistently year after year.